- Home
- FGEN vs BTAI Comparison
FGEN vs BTAI Comparison
Compare FGEN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- BTAI
- Stock Information
- Founded
- FGEN 1993
- BTAI 2017
- Country
- FGEN United States
- BTAI United States
- Employees
- FGEN N/A
- BTAI N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- BTAI Health Care
- Exchange
- FGEN Nasdaq
- BTAI Nasdaq
- Market Cap
- FGEN 45.0M
- BTAI 52.7M
- IPO Year
- FGEN 2014
- BTAI 2018
- Fundamental
- Price
- FGEN $11.16
- BTAI $2.48
- Analyst Decision
- FGEN Strong Buy
- BTAI Buy
- Analyst Count
- FGEN 2
- BTAI 5
- Target Price
- FGEN $146.50
- BTAI $32.80
- AVG Volume (30 Days)
- FGEN 30.7K
- BTAI 1.6M
- Earning Date
- FGEN 11-11-2025
- BTAI 11-13-2025
- Dividend Yield
- FGEN N/A
- BTAI N/A
- EPS Growth
- FGEN N/A
- BTAI N/A
- EPS
- FGEN N/A
- BTAI N/A
- Revenue
- FGEN $7,346,000.00
- BTAI $868,000.00
- Revenue This Year
- FGEN N/A
- BTAI N/A
- Revenue Next Year
- FGEN N/A
- BTAI $614.78
- P/E Ratio
- FGEN N/A
- BTAI N/A
- Revenue Growth
- FGEN N/A
- BTAI N/A
- 52 Week Low
- FGEN $4.50
- BTAI $1.17
- 52 Week High
- FGEN $21.94
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- FGEN 46.07
- BTAI 38.09
- Support Level
- FGEN $11.36
- BTAI $2.47
- Resistance Level
- FGEN $12.13
- BTAI $2.70
- Average True Range (ATR)
- FGEN 0.54
- BTAI 0.21
- MACD
- FGEN -0.20
- BTAI -0.00
- Stochastic Oscillator
- FGEN 8.97
- BTAI 9.74
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.